



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

4 October 2021

COVID-19 vaccination as of 0:00 today (cumulative since 26 February 2021) (n, %)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
Population*	51,349,116	9,505,868	3,356,587	2,401,110	2,915,839	1,441,552	1,454,011	1,130,315	354,705
New (1st dose)	3,404	637	139	81	271	26	91	37	17
New (2nd dose)	33,187	6,422	1,254	1,130	2,339	261	1,137	432	203
Total (1st dose)	39,714,000	7,445,243	2,558,595	1,770,609	2,254,367	1,097,619	1,094,040	849,939	252,719
Total (2nd dose)	27,016,188	5,029,684	1,796,118	1,203,373	1,485,949	750,467	719,310	562,839	167,866
% (1st dose)	77.3	78.3	76.2	73.7	77.3	76.1	75.2	75.2	71.2
% (2nd dose)	52.6	52.9	53.5	50.1	51.0	52.1	49.5	49.8	47.3
	Province								
	Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam	Jeju
Population*	13,315,895	1,529,586	1,591,009	2,106,946	1,792,694	1,839,432	2,623,028	3,321,362	669,177
New (1st dose)	1,521	41	81	117	72	48	94	79	52
New (2nd dose)	14,291	330	897	1,194	617	513	737	794	636
Total (1st dose)	10,354,900	1,190,999	1,256,987	1,660,161	1,408,423	1,474,621	2,013,943	2,529,166	501,669
Total (2nd dose)	6,798,983	863,811	863,462	1,147,002	1,017,018	1,102,520	1,434,095	1,732,511	341,180
% (1st dose)	77.8	77.9	79.0	78.8	78.6	80.2	76.8	76.1	75.0
% (2nd dose)	51.1	56.5	54.3	54.4	56.7	59.9	54.7	52.2	51.0

※ Figures subject to correction recording update



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

4 October 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		1,673 (100)	319,777 (100)	617
Sex	Male	1,025 (61.27)	168,355 (52.65)	652
	Female	648 (38.73)	151,422 (47.35)	583
Age	80 or above	33 (1.97)	7,890 (2.47)	394
	70-79	57 (3.41)	14,651 (4.58)	396
	60-69	158 (9.44)	35,749 (11.18)	530
	50-59	190 (11.36)	51,948 (16.25)	601
	40-49	275 (16.44)	51,394 (16.07)	620
	30-39	276 (16.50)	50,720 (15.86)	738
	20-29	384 (22.95)	61,801 (19.33)	908
	10-19	188 (11.24)	28,124 (8.79)	587
	0-9	112 (6.69)	17,500 (5.47)	441

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		6 (100)	2,513 (100)	0.79	348 (100)
Sex	Male	4 (66.67)	1,272 (50.62)	0.76	206 (59.20)
	Female	2 (33.33)	1,241 (49.38)	0.82	142 (40.80)
Age	80 or above	1 (16.67)	1,255 (49.94)	15.91	54 (15.52)
	70-79	1 (16.67)	678 (26.98)	4.63	76 (21.84)
	60-69	3 (50.00)	360 (14.33)	1.01	79 (22.70)
	50-59	0 (0.00)	155 (6.17)	0.30	58 (16.67)
	40-49	0 (0.00)	34 (1.35)	0.07	50 (14.37)
	30-39	0 (0.00)	20 (0.80)	0.04	21 (6.03)
	20-29	1 (16.67)	11 (0.44)	0.02	9 (2.59)
	10-19	0 (0.00)	0 (0.00)	0.00	1 (0.29)
	0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

Severe/Critical Cases for past 2 weeks

	9.21	9.22	9.23	9.24	9.25	9.26	9.27	9.28	9.29	9.30	10.1	10.2	10.3	10.4
Total	328	317	312	309	339	320	319	324	331	336	323	336	346	348

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

4 October 2021

Adverse Events Following COVID-19 Vaccination

(n, %)

		Total (A=B+C)	Non- serious AEFI (B)	Serious AEFI (C)				Vaccinations administered (D)	% reported as AEFI (E=A/D)
				Subtotal (C=C1+C2+C3)	Death (C1)	Anaphylaxis suspected (C2)	Others (C3)		
Total	Oct 3	2,526	2,482	44	1	6	37	65,282,635	0.44
	Oct 4	1,030	1,017	13	2	0	11		
	Total	286,942	275,920	11,022	716	1,252	9,054		
AZ	Oct 3	69	65	4	0	0	4	19,892,512	0.52
	Oct 4	14	13	1	1	0	0		
	Total	103,189	98,223	4,966	309	310	4,347		
PF	Oct 3	1,143	1,116	27	1	3	23	35,654,179	0.36
	Oct 4	498	490	8	0	0	8		
	Total	130,115	125,136	4,979	373	736	3,870		
M	Oct 3	1,307	1,294	13	0	3	10	8,288,391	0.55
	Oct 4	518	514	4	1	0	3		
	Total	45,275	44,552	723	23	159	541		
J	Oct 3	7	7	0	0	0	0	1,447,553	0.58
	Oct 4	0	0	0	0	0	0		
	Total	8,363	8,009	354	11	47	296		

A. Based on cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

B. Non-serious AE includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

C. Serious AEFI includes:

Death;

Anaphylaxis suspected (including anaphylactoid reactions);

Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatening

※ Updated weekly

※ Subject to change upon new findings

※ AZ=AstraZeneca; Pf=Pfizer; J=Janssen, M=Moderna

※ Total death toll is 959 (AZ: 412, PF: 510, M: 24, J: 13) including 285 patients whose status have changed to deceased



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

4 October 2021

Adverse Events Following Second Dose of COVID-19 Vaccination (by gender) (as of October 3, 2021)

(n)

		Vaccinations administered	Total AEFI ^a	Non-serious AEFI ^b	Serious AEFI ^c			
					Subtotal	Death ^①	Anaphylaxis suspected ^②	Others ^③
Male	Subtotal	31,467,374	95,646	90,869	4,777	432	396	3,949
	1st dose	19,647,677	68,574	65,064	3,510	275	355	2,880
	2nd dose	11,819,697	27,072	25,805	1,267	157	41	1,069
Female	Subtotal	33,778,348	190,266	184,034	6,232	282	856	5,094
	1st dose	20,062,793	131,875	127,226	4,649	176	741	3,732
	2nd dose	13,715,555	58,391	56,808	1,583	106	115	1,362

a. Based on cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

b. Includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

c. Serious AEFI includes:

- ① Death;
- ② Anaphylaxis suspected (including anaphylactoid reactions);
- ③ Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatening

※ Subject to change upon new findings



KDCA

Korea Disease Control and
Prevention Agency

Updates on COVID-19 in Republic of Korea

4 October 2021

Adverse Events Following COVID-19 Vaccination (by age) (as of October 3, 2021)

(n, %)

		Vaccinations administered	Total AEFI ^a (reporting rate, %)	Non-serious AEFI ^b	Serious AEFI ^c			
					Subtotal	Death ^①	Anaphylaxis suspected ^②	Others ^③
Ages 0-17	Subtotal	32,321	145	143	2	0	1	1
	1st dose	16,395	42	41	1	0	1	0
	2nd dose	15,926	103	102	1	0	0	1
Ages 18-29	Subtotal	9,507,524	48,977	47,818	1,159	11	363	785
	1st dose	6,640,747	34,324	33,405	919	10	326	583
	2nd dose	2,866,777	14,653	14,413	240	1	37	202
Ages 30-39	Subtotal	7,463,092	42,892	41,678	1,214	19	275	920
	1st dose	5,685,690	34,286	33,230	1,056	15	257	784
	2nd dose	1,777,402	8,606	8,448	158	4	18	136
Ages 40-49	Subtotal	10,037,366	41,469	40,238	1,231	29	252	950
	1st dose	7,252,996	31,306	30,296	1,010	25	228	757
	2nd dose	2,784,370	10,163	9,942	221	4	24	193
Ages 50-59	Subtotal	14,689,604	54,105	52,497	1,608	79	180	1,349
	1st dose	8,017,674	34,231	32,965	1,266	61	147	1,058
	2nd dose	6,671,930	19,874	19,532	342	18	33	291
Ages 60-69	Subtotal	12,967,858	61,523	58,687	2,836	161	105	2,570
	1st dose	6,727,007	45,155	43,025	2,130	97	86	1,947
	2nd dose	6,240,851	16,368	15,662	706	64	19	623
Ages 70-79	Subtotal	6,866,969	26,692	24,884	1,808	162	36	1,610
	1st dose	3,493,897	16,618	15,455	1,163	92	25	1,046
	2nd dose	3,373,072	10,074	9,429	645	70	11	564
Ages 80 and above	Subtotal	3,680,988	10,109	8,958	1,151	253	40	858
	1st dose	1,876,064	4,487	3,873	614	151	26	437
	2nd dose	1,804,924	5,622	5,085	537	102	14	421

a. Based on cases reported as suspected cases of adverse events following immunization (AEFI) by healthcare institutions; Does not imply causal relationship; Report status classification subject to change if new information is added

b. Includes common non-serious AEFI symptoms such as redness at the injection site, pain, swelling, muscle pain, fever, headache, and chills

c. Serious AEFI includes:

① Death;

② Anaphylaxis suspected (including anaphylactoid reactions);

③ Adverse events of special interest (AESI), ICU admission, persistent or significant disability or incapacity, congenital anomaly/birth defect, life-threatening

※ Subject to change upon new findings